BLA Resubmitted to FDA for On-Body Injector Presentation of Pegfilgrastim-cbqv
The biologics license application (BLA) seeking the approval of the on-body injector presentation of pegfilgrastim-cbqv, a biosimilar of Neulasta Onpro, has been resubmitted to the FDA for review.